A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo

Science Translational Medicine

Volumn 5, Issue 181, 2013, Pages

  Saito, Yoriko ^a   Yuki, Hitomi ^b   Kuratani, Mitsuo ^b   Hashizume, Yoshinobu ^b   Takagi, Shinsuke ^a,c   Honma, Teruki ^b   Tanaka, Akiko ^b   Shirouzu, Mikako ^b   Mikuni, Junko ^b   Handa, Noriko ^b   Ogahara, Ikuko ^a   Sone, Akiko ^a   Najima, Yuho ^a   Tomabechi, Yuri ^a   Wakiyama, Motoaki ^b   Uchida, Naoyuki ^c   Tomizawa Murasawa, Mariko ^a   Kaneko, Akiko ^a   Tanaka, Satoshi ^d   Suzuki, Nahoko ^a   Kajita, Hiroshi ^a   Aoki, Yuki ^a   Ohara, Osamu ^a   Shultz, Leonard D ^e   Fukami, Takehiro ^b   Goto, Toshio ^b   Taniguchi, Shuichi ^c   Yokoyama, Shigeyuki ^b   Ishikawa, Fumihiko ^a   more..

^a Institute of Physical and Chemical Research   (Japan)

^b RIKEN   (Japan)

^c TORANOMON HOSPITAL   (Japan)

^d Nippon Becton Dickinson   (Japan)

^e JACKSON LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; GLUTAMIC ACID; HEMATOPOIETIC CELL KINASE; METHIONINE; PHENYLALANINE; PHOSPHOTRANSFERASE INHIBITOR; PYRROLOPYRIMIDINE DERIVATIVE; RK 20444; RK 20445; RK 20446; RK 20448; RK 20449; RK 20450; RK 20451; RK 24466; THREONINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CANCER STEM CELL; CLINICAL ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG SCREENING; DRUG STRUCTURE; ENZYME ASSAY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA STEM CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STRUCTURE ANALYSIS; TUMOR XENOGRAFT;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOPOIESIS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MIDDLE AGED; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-HCK; PYRIMIDINES; PYRROLES; RNA, SMALL INTERFERING; SMALL MOLECULE LIBRARIES; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84877729772     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004387     Document Type: Article

References (61)

1. C. C. Kumar, Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer 2, 95-107 (2011).
2. T. Büchner, W. E. Berdel, C. Haferlach, T. Haferlach, S. Schnittger, C. Müller-Tidow, J. Braess, K. Spiekermann, J. Kienast, P. Staib, A. Grüneisen, W. Kern, A. Reichle, G. Maschmeyer, C. Aul, E. Lengfelder, M. C. Sauerland, A. Heinecke, B. Wörmann, W. Hiddemann, Agerelated risk profile and chemotherapy dose response in acute myeloid leukemia: A study by the German Acute Myeloid Leukemia Cooperative Group. J. Clin. Oncol. 27, 61-69 (2009).
3. A. K. Burnett, R. K. Hills, D. W. Milligan, A. H. Goldstone, A. G. Prentice, M. F. McMullin, A. Duncombe, B. Gibson, K. Wheatley, Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: Results of the MRC AML12 trial. J. Clin. Oncol. 28, 586-595 (2010).
4. H. F. Fernandez, Z. Sun, X. Yao, M. R. Litzow, S. M. Luger, E. M. Paietta, J. Racevskis, G. W. Dewald, R. P. Ketterling, J. M. Bennett, J. M. Rowe, H. M. Lazarus, M. S. Tallman, Anthracycline dose intensification in acute myeloid leukemia. N. Engl. J. Med. 361, 1249-1259 (2009).
5. F. Mandelli, M. Vignetti, S. Suciu, R. Stasi, M. C. Petti, G. Meloni, P. Muus, F. Marmont, J. P. Marie, B. Labar, X. Thomas, F. Di Raimondo, R. Willemze, V. Liso, F. Ferrara, L. Baila, P. Fazi, R. Zittoun, S. Amadori, T. de Witte, Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: The EORTC and GIMEMA Groups Study AML-10. J. Clin. Oncol. 27, 5397-5403 (2009).
6. C. T. Jordan, M. L. Guzman, M. Noble, Cancer stem cells. N. Engl. J. Med. 355, 1253-1261 (2006).
7. M. Y. Konopleva, C. T. Jordan, Leukemia stem cells and microenvironment: Biology and therapeutic targeting. J. Clin. Oncol. 29, 591-599 (2011).
8. K. Eppert, K. Takenaka, E. R. Lechman, L. Waldron, B. Nilsson, P. van Galen, K. H. Metzeler, A. Poeppl, V. Ling, J. Beyene, A. J. Canty, J. S. Danska, S. K. Bohlander, C. Buske, M. D. Minden, T. R. Golub, I. Jurisica, B. L. Ebert, J. E. Dick, Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17, 1086-1093 (2011).
9. A. J. Gentles, S. K. Plevritis, R. Majeti, A. A. Alizadeh, Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 304, 2706-2715 (2010).
10. F. Ishikawa, S. Yoshida, Y. Saito, A. Hijikata, H. Kitamura, S. Tanaka, R. Nakamura, T. Tanaka, H. Tomiyama, N. Saito, M. Fukata, T. Miyamoto, B. Lyons, K. Ohshima, N. Uchida, S. Taniguchi, O. Ohara, K. Akashi, M. Harada, L. D. Shultz, Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat. Biotechnol. 25, 1315-1321 (2007).
11. Y. Saito, N. Uchida, S. Tanaka, N. Suzuki, M. Tomizawa-Murasawa, A. Sone, Y. Najima, S. Takagi, Y. Aoki, A. Wake, S. Taniguchi, L. D. Shultz, F. Ishikawa, Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat. Biotechnol. 28, 275-280 (2010).
12. Y. Saito, H. Kitamura, A. Hijikata, M. Tomizawa-Murasawa, S. Tanaka, S. Takagi, N. Uchida, N. Suzuki, A. Sone, Y. Najima, H. Ozawa, A. Wake, S. Taniguchi, L. D. Shultz, O. Ohara, F. Ishikawa, Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci. Transl. Med. 2, 17ra9 (2010).
13. E. Ingley, Src family kinases: Regulation of their activities, levels and identification of new pathways. Biochim. Biophys. Acta 1784, 56-65 (2008).
14. M. B. Miranda, D. E. Johnson, Signal transduction pathways that contribute to myeloid differentiation. Leukemia 21, 1363-1377 (2007).
15. K. W. Harder, L. M. Parsons, J. Armes, N. Evans, N. Kountouri, R. Clark, C. Quilici, D. Grail, G. S. Hodgson, A. R. Dunn, M. L. Hibbs, Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage. Immunity 15, 603-615 (2001).
16. C. H. Mermel, M. L. McLemore, F. Liu, S. Pereira, J. Woloszynek, C. A. Lowell, D. C. Link, Src family kinases are important negative regulators of G-CSF-dependent granulopoiesis. Blood 108, 2562-2568 (2006).
17. Y. Hu, Y. Liu, S. Pelletier, E. Buchdunger, M. Warmuth, D. Fabbro, M. Hallek, R. A. Van Etten, S. Li, Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat. Genet. 36, 453-461 (2004).
18. D. Linnekin, C. S. DeBerry, S. Mou, Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells. J. Biol. Chem. 272, 27450-27455 (1997).
19. O. Mitina, M. Warmuth, G. Krause, M. Hallek, A. Obermeier, Src family tyrosine kinases phosphorylate Flt3 on juxtamembrane tyrosines and interfere with receptor maturation in a kinase-dependent manner. Ann. Hematol. 86, 777-785 (2007).
20. B. O'Laughlin-Bunner, N. Radosevic, M. L. Taylor, Shivakrupa, C. DeBerry, D. D. Metcalfe, M. Zhou, C. Lowell, D. Linnekin, Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells. Blood 98, 343-350 (2001).
21. M. Okamoto, F. Hayakawa, Y. Miyata, K. Watamoto, N. Emi, A. Abe, H. Kiyoi, M. Towatari, T. Naoe, Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD. Leukemia 21, 403-410 (2007).
22. L. J. Robinson, J. Xue, S. J. Corey, Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations. Exp. Hematol. 33, 469-479 (2005).
23. M. B. Wilson, S. J. Schreiner, H. J. Choi, J. Kamens, T. E. Smithgall, Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 21, 8075-8088 (2002).
24. L. D. Shultz, F. Ishikawa, D. L. Greiner, Humanized mice in translational biomedical research. Nat. Rev. Immunol. 7, 118-130 (2007).
25. T. Pene-Dumitrescu, L. F. Peterson, N. J. Donato, T. E. Smithgall, An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broadspectrum Src family kinase inhibitor A-419259. Oncogene 27, 7055-7069 (2008).
26. K. Tsuganezawa, H. Watanabe, L. Parker, H. Yuki, S. Taruya, Y. Nakagawa, D. Kamei, M. Mori, N. Ogawa, Y. Tomabechi, N. Handa, T. Honma, S. Yokoyama, H. Kojima, T. Okabe, T. Nagano, A. Tanaka, A novel Pim-1 kinase inhibitor targeting residues that bind the substrate peptide. J. Mol. Biol. 417, 240-252 (2012).
27. J. H. Zhang, T. D. Chung, K. R. Oldenburg, A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen 4, 67-73 (1999).
28. J. B. Baell, G. A. Holloway, New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 53, 2719-2740 (2010).
29. T. Schindler, F. Sicheri, A. Pico, A. Gazit, A. Levitzki, J. Kuriyan, Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol. Cell 3, 639-648 (1999).
30. R. A. Friesner, J. L. Banks, R. B. Murphy, T. A. Halgren, J. J. Klicic, D. T. Mainz, M. P. Repasky, E. H. Knoll, M. Shelley, J. K. Perry, D. E. Shaw, P. Francis, P. S. Shenkin, Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47, 1739-1749 (2004).
31. D. J. Calderwood, D. N. Johnston, R. Munschauer, P. Rafferty, Pyrrolo[2,3-d]pyrimidines containing diverse N-7 substituents as potent inhibitors of Lck. Bioorg. Med. Chem. Lett. 12, 1683-1686 (2002).
32. B. Apsel, J. A. Blair, B. Gonzalez, T. M. Nazif, M. E. Feldman, B. Aizenstein, R. Hoffman, R. L. Williams, K. M. Shokat, Z. A. Knight, Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4, 691-699 (2008).
33. A. Y. Choo, S. O. Yoon, S. G. Kim, P. P. Roux, J. Blenis, Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl. Acad. Sci. U.S.A. 105, 17414-17419 (2008).
34. C. C. Thoreen, S. A. Kang, J. W. Chang, Q. Liu, J. Zhang, Y. Gao, L. J. Reichling, T. Sim, D. M. Sabatini, N. S. Gray, An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023-8032 (2009).
35. K. Yu, L. Toral-Barza, C. Shi, W. G. Zhang, J. Lucas, B. Shor, J. Kim, J. Verheijen, K. Curran, D. J. Malwitz, D. C. Cole, J. Ellingboe, S. Ayral-Kaloustian, T. S. Mansour, J. J. Gibbons, R. T. Abraham, P. Nowak, A. Zask, Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 69, 6232-6240 (2009).
36. T. Kindler, D. B. Lipka, T. Fischer, FLT3 as a therapeutic target in AML: Still challenging after all these years. Blood 116, 5089-5102 (2010).
37. P. Paschka, G. Marcucci, A. S. Ruppert, K. Mrózek, H. Chen, R. A. Kittles, T. Vukosavljevic, D. Perrotti, J. W. Vardiman, A. J. Carroll, J. E. Kolitz, R. A. Larson, C. D. Bloomfield; Cancer and Leukemia Group B, Adverse prognostic significance of KITmutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B Study. J. Clin. Oncol. 24, 3904-3911 (2006).
38. R. F. Schlenk, K. Döhner, J. Krauter, S. Fröhling, A. Corbacioglu, L. Bullinger, M. Habdank, D. Späth, M. Morgan, A. Benner, B. Schlegelberger, G. Heil, A. Ganser, H. Döhner; German- Austrian Acute Myeloid Leukemia Study Group, Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 358, 1909-1918 (2008).
39. C. Dos Santos, C. Demur, V. Bardet, N. Prade-Houdellier, B. Payrastre, C. Récher, A critical role for Lyn in acute myeloid leukemia. Blood 111, 2269-2279 (2008).
40. K. U. Birkenkamp, M. Geugien, H. Schepers, J. Westra, H. H. Lemmink, E. Vellenga, Constitutive NF-kB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKBdependent pathway. Leukemia 18, 103-112 (2004).
41. M. L. Guzman, S. J. Neering, D. Upchurch, B. Grimes, D. S. Howard, D. A. Rizzieri, S. M. Luger, C. T. Jordan, Nuclear factor-kB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98, 2301-2307 (2001).
42. F. Hayakawa, M. Towatari, H. Kiyoi, M. Tanimoto, T. Kitamura, H. Saito, T. Naoe, Tandemduplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19, 624-631 (2000).
43. M. Milella, S. M. Kornblau, Z. Estrov, B. Z. Carter, H. Lapillonne, D. Harris, M. Konopleva, S. Zhao, E. Estey, M. Andreeff, Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J. Clin. Invest. 108, 851-859 (2001).
44. C. Récher, O. Beyne-Rauzy, C. Demur, G. Chicanne, C. Dos Santos, V. M. Mas, D. Benzaquen, G. Laurent, F. Huguet, B. Payrastre, Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105, 2527-2534 (2005).
45. P. Sujobert, V. Bardet, P. Cornillet-Lefebvre, J. S. Hayflick, N. Prie, F. Verdier, B. Vanhaesebroeck, O. Muller, F. Pesce, N. Ifrah, M. Hunault-Berger, C. Berthou, B. Villemagne, E. Jourdan, B. Audhuy, E. Solary, B. Witz, J. L. Harousseau, C. Himberlin, T. Lamy, B. Lioure, J. Y. Cahn, F. Dreyfus, P. Mayeux, C. Lacombe, D. Bouscary, Essential role for the p110d isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106, 1063-1066 (2005).
46. Q. Xu, S. E. Simpson, T. J. Scialla, A. Bagg, M. Carroll, Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102, 972-980 (2003).
47. R. Polak, M. Buitenhuis, The PI3K/PKB signaling module as key regulator of hematopoiesis: Implications for therapeutic strategies in leukemia. Blood 119, 911-923 (2012).
48. S. Sharma, G. U. Gurudutta, N. K. Satija, S. Pati, F. Afrin, P. Gupta, Y. K. Verma, V. K. Singh, R. P. Tripathi, Stem cell c-KIT and HOXB4 genes: Critical roles and mechanisms in selfrenewal, proliferation, and differentiation. Stem Cells Dev. 15, 755-778 (2006).
49. P. Ray, N. Krishnamoorthy, T. B. Oriss, A. Ray, Signaling of c-kit in dendritic cells influences adaptive immunity. Ann. N. Y. Acad. Sci. 1183, 104-122 (2010).
50. H. Leischner, C. Albers, R. Grundler, E. Razumovskaya, K. Spiekermann, S. Bohlander, L. Rönnstrand, K. Götze, C. Peschel, J. Duyster, SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML. Blood 119, 4026-4033 (2012).
51. A. Gaulton, L. J. Bellis, A. P. Bento, J. Chambers, M. Davies, A. Hersey, Y. Light, S. McGlinchey, D. Michalovich, B. Al-Lazikani, J. P. Overington, ChEMBL: A large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100-D1107 (2012).
52. C. McInnes, Virtual screening strategies in drug discovery. Curr. Opin. Chem. Biol. 11, 494-502 (2007).
53. G. G. Dubinina, O. O. Chupryna, M. O. Platonov, P. O. Borisko, G. V. Ostrovska, A. O. Tolmachov, A. A. Shtil, In silico design of protein kinase inhibitors: Successes and failures. Anticancer Agents Med. Chem. 7, 171-188 (2007).
54. T. Sato, H. Watanabe, K. Tsuganezawa, H. Yuki, J. Mikuni, S. Yoshikawa, M. Kukimoto-Niino, T. Fujimoto, Y. Terazawa, M. Wakiyama, H. Kojima, T. Okabe, T. Nagano, M. Shirouzu, S. Yokoyama, A. Tanaka, T. Honma, Identification of novel drug-resistant EGFR mutant inhibitors by in silico screening using comprehensive assessments of protein structures. Bioorg. Med. Chem. 20, 3756-3767 (2012).
55. W. Kabsch, XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010).
56. Z. Otwinowski, W. Minor, Processing of X-ray diffraction data collected in oscillation mode. Macromol. Crystallogr. A 276, 307-326 (1997).
57. Collaborative Computational Project, Number 4, The CCP4 suite: Programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763 (1994).
58. A. Burchat, D. W. Borhani, D. J. Calderwood, G. C. Hirst, B. Li, R. F. Stachlewitz, Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection. Bioorg. Med. Chem. Lett. 16, 118-122 (2006).
59. P. Emsley, K. Cowtan, Coot: Model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
60. M. R. Janes, J. J. Limon, L. So, J. Chen, R. J. Lim, M. A. Chavez, C. Vu, M. B. Lilly, S. Mallya, S. T. Ong, M. Konopleva, M. B. Martin, P. Ren, Y. Liu, C. Rommel, D. A. Fruman, Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat. Med. 16, 205-213 (2010).
61. F. Sicheri, I. Moarefi, J. Kuriyan, Crystal structure of the Src family tyrosine kinase Hck. Nature 385, 602-609 (1997).